Abstract
BACKGROUND AND OBJECTIVE: To evaluate the safety and efficacy of ziv-aflibercept (Zaltrap; SanofiAventis, Bridgewater, NJ/Regeneron Pharmaceuticals, T......
小提示:本篇文献需要登录阅读全文,点击跳转登录